• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab.

作者信息

Roth Patrick, Valavanis Antonios, Weller Michael

机构信息

Department of Neurology and Brain Tumour Centre, University Hospital and University of Zurich, Zurich, Switzerland.

Department of Neuroradiology, University Hospital Zurich, Switzerland.

出版信息

Neuro Oncol. 2017 Mar 1;19(3):454-456. doi: 10.1093/neuonc/now265.

DOI:10.1093/neuonc/now265
PMID:28039369
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5464329/
Abstract
摘要

相似文献

1
Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab.通过纳武单抗抗PD-1治疗胶质母细胞瘤初始假性进展后的长期控制和部分缓解
Neuro Oncol. 2017 Mar 1;19(3):454-456. doi: 10.1093/neuonc/now265.
2
Pseudoprogression: an indicator for cure in combined immunotherapy?假性进展：联合免疫治疗中的治愈指标？
Immunotherapy. 2019 Sep;11(13):1087-1093. doi: 10.2217/imt-2019-0034. Epub 2019 Jul 30.
3
Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.不可切除的非转移性原发性黑色素瘤：抗程序性细胞死亡受体1治疗后完全缓解
Acta Derm Venereol. 2019 Jan 1;99(1):107-108. doi: 10.2340/00015555-3028.
4
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.抗 PD-1 免疫疗法治疗胶质母细胞瘤的免疫和基因组相关性。
Nat Med. 2019 Mar;25(3):462-469. doi: 10.1038/s41591-019-0349-y. Epub 2019 Feb 11.
5
Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.靶向多个受体以提高检查点阻断疗效。
Int J Mol Sci. 2019 Jan 4;20(1):158. doi: 10.3390/ijms20010158.
6
Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma.霍奇金淋巴瘤患者停用抗程序性死亡蛋白1（anti-PD-1）治疗后出现长期缓解。
Blood. 2018 Jun 21;131(25):2856-2859. doi: 10.1182/blood-2018-03-841262. Epub 2018 May 3.
7
Outcomes of Australian patients receiving non-funded anti-PD-1 immune checkpoint inhibitors for non-melanoma cancers.接受非资助性抗程序性死亡蛋白1免疫检查点抑制剂治疗非黑色素瘤癌症的澳大利亚患者的治疗结果。
Asia Pac J Clin Oncol. 2018 Aug;14(4):337-342. doi: 10.1111/ajco.12867. Epub 2018 Mar 1.
8
Nivolumab-induced aplastic anemia: A case report and literature review.纳武单抗诱发的再生障碍性贫血：一例病例报告及文献综述
J Oncol Pharm Pract. 2019 Jan;25(1):221-225. doi: 10.1177/1078155217726159. Epub 2017 Aug 21.
9
Thoracic Imaging of Non-Small Cell Lung Cancer Treated With Anti-programmed Death Receptor-1 Therapy.接受抗程序性死亡受体-1治疗的非小细胞肺癌的胸部影像学表现
Curr Probl Diagn Radiol. 2019 Mar-Apr;48(2):142-147. doi: 10.1067/j.cpradiol.2018.01.005. Epub 2018 Jan 31.
10
Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma.信迪利单抗：经典型霍奇金淋巴瘤中的另一种有效免疫检查点抑制剂。
Lancet Haematol. 2019 Jan;6(1):e2-e3. doi: 10.1016/S2352-3026(18)30210-2.

引用本文的文献

1
A new paradigm for immunotherapy in glioblastoma.胶质母细胞瘤免疫治疗的新范式。
Nat Med. 2025 May;31(5):1404-1405. doi: 10.1038/s41591-025-03607-9.
2
Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth.创新型肿瘤治疗设备OM-100通过增强抗PD-1免疫疗法对胶质母细胞瘤生长的抗肿瘤作用。
Sci Rep. 2024 Aug 8;14(1):18444. doi: 10.1038/s41598-024-67437-4.
3
Exploring MAP2K3 as a prognostic biomarker and potential immunotherapy target in glioma treatment.探索丝裂原活化蛋白激酶激酶3（MAP2K3）作为胶质瘤治疗中的预后生物标志物和潜在免疫治疗靶点。
Front Neurol. 2024 Jun 13;15:1387743. doi: 10.3389/fneur.2024.1387743. eCollection 2024.
4
Revolutionizing Glioblastoma Treatment: A Comprehensive Overview of Modern Therapeutic Approaches.革命性的脑胶质瘤治疗方法：现代治疗方法的全面概述。
Int J Mol Sci. 2024 May 26;25(11):5774. doi: 10.3390/ijms25115774.
5
A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives.免疫疗法治疗高级别胶质瘤的系统评价：从过去中学习，塑造未来的视角。
Neurol Sci. 2024 Jun;45(6):2561-2578. doi: 10.1007/s10072-024-07350-w. Epub 2024 Feb 3.
6
ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-guided Analysis.ERK1/2 磷酸化预测颅内和辅助 PD-1/CTLA-4 免疫治疗后复发性胶质母细胞瘤的生存：一项 REMARK 指导分析。
Clin Cancer Res. 2024 Jan 17;30(2):379-388. doi: 10.1158/1078-0432.CCR-23-1889.
7
Genomic analysis of immunogenic cell death-related subtypes for predicting prognosis and immunotherapy outcomes in glioblastoma multiforme.多形性胶质母细胞瘤中免疫原性细胞死亡相关亚型的基因组分析以预测预后和免疫治疗结果
Open Med (Wars). 2023 Jun 2;18(1):20230716. doi: 10.1515/med-2023-0716. eCollection 2023.
8
Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment.胶质母细胞瘤的免疫检查点阻断：从肿瘤异质性到个体化治疗。
J Clin Invest. 2023 Jan 17;133(2):e163447. doi: 10.1172/JCI163447.
9
Optimization of cancer immunotherapy through pyroptosis: A pyroptosis-related signature predicts survival benefit and potential synergy for immunotherapy in glioma.通过细胞焦亡优化癌症免疫治疗：细胞焦亡相关特征可预测胶质母细胞瘤免疫治疗的生存获益和潜在协同作用。
Front Immunol. 2022 Aug 3;13:961933. doi: 10.3389/fimmu.2022.961933. eCollection 2022.
10
Regulation of temozolomide resistance via lncRNAs: Clinical and biological properties of lncRNAs in gliomas (Review).通过长链非编码 RNA 调节替莫唑胺耐药性：胶质瘤中长链非编码 RNA 的临床和生物学特性（综述）。
Int J Oncol. 2022 Sep;61(3). doi: 10.3892/ijo.2022.5391. Epub 2022 Jul 7.

本文引用的文献

1
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.神经肿瘤学中的免疫治疗反应评估：RANO工作组报告
Lancet Oncol. 2015 Nov;16(15):e534-e542. doi: 10.1016/S1470-2045(15)00088-1.
2
Immunotherapy for glioblastoma: concepts and challenges.胶质母细胞瘤的免疫疗法：概念与挑战。
Curr Opin Neurol. 2015 Dec;28(6):639-46. doi: 10.1097/WCO.0000000000000249.
3
Prospects of immune checkpoint modulators in the treatment of glioblastoma.免疫检查点调节剂在胶质母细胞瘤治疗中的前景
Nat Rev Neurol. 2015 Sep;11(9):504-14. doi: 10.1038/nrneurol.2015.139. Epub 2015 Aug 11.